
Half of US states are expected to restrict or ban abortion following the Supreme Court’s leaked draft majority opinion; Bayer’s darolutamide (Nubeqa) received FDA priority review as a treatment for metastatic hormone-sensitive prostate cancer; Biogen stops marketing its controversial Alzheimer drug as its CEO plans to step down.




























